In Re Synthroid Marketing Litigation

201 F. Supp. 2d 861, 2002 U.S. Dist. LEXIS 8408, 2002 WL 1066355
CourtDistrict Court, N.D. Illinois
DecidedMay 9, 2002
Docket97 C 6017
StatusPublished
Cited by7 cases

This text of 201 F. Supp. 2d 861 (In Re Synthroid Marketing Litigation) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Synthroid Marketing Litigation, 201 F. Supp. 2d 861, 2002 U.S. Dist. LEXIS 8408, 2002 WL 1066355 (N.D. Ill. 2002).

Opinion

MEMORANDUM OPINION AND ORDER

BUCKLO, District Judge.

This opinion discusses attorneys’ fees and costs in a large class action lawsuit. Synthroid is the brand name of a synthetic version of levothyroxine sodium, a drug used to treat thyroid disorders. In 1990, Betty J. Dong, a pharmacy professor at the University of California, San Francis *864 co, wrote a report for Knoll Pharmaceutical Company concluding that there were cheaper drugs that were bioequivalents. Knoll refused to allow publication of the report, but when Dong’s conclusions were publicized anyway, Knoll, embarrassed, relented, and the Dong report appeared in the Journal of the American Medical Association in 1997. Meanwhile, after the initial release of Dong’s conclusions, consumers and third party payers filed class action lawsuits against various defendants, including Knoll, BASF Corp., and Boots Pharmaceuticals, alleging that they had lied about or suppressed the existence of bioequivalents and overcharged consumers and their insurers for their brand name product, Synthroid. The various claims were transferred and consolidated before me under the multi-district litigation statute in August 1997. The parties came to me with a settlement proposal that I rejected as inadequate in an order of August 17, 1998. I certified two classes, one of consumers and one of third party payers.

On August 5, 2000, I approved a new settlement proposal creating a common fund of over $150 million to be divided between the two classes. See 110 F.Supp.2d 676 (N.D.Ill.2000). The part of my opinion approving the settlement was affirmed by the Seventh Circuit, 264 F.3d 712 (7th Cir.2001). That court, however, remanded those portions of my order that dealt with attorneys’ fees and costs. Consumer class counsel renew their request for 29% of the consumer settlement amount, as of October 2001, about $96,200,000 (including interest), and around $1,500,000 in costs. Again, I give them less than they ask for, but a lot of money nonetheless. Counsel for the third party payer (“TPP”) class has again asked for attorneys’ fees in the amount of about 22% of the class settlement funds (principal amount plus interest), which fund, as of October 2001, stood at about $48,500,000 as well as for around $620,100 in expenses. I approve this fee petition. Objectors’ counsel also asks for attorneys’ fees, and I deny these.

I. Procedural Background

In my previous opinion, I noted that attorneys’ fees in a class action require court approval, in part because at this stage of the case, the role of class counsel now changes from that of fiduciaries to claimants against the fund created for the clients’ benefit. 110 F.Supp.2d at 683 (citing Cook v. Niedert, 142 F.3d 1004, 1011 (7th Cir.1998)). In awarding fees, a court must protect the clients’ interests without undermining the incentive for attorneys to bring meritorious class actions on an inescapably contingent basis. Id. (citing Florin v. Nationsbank of Georgia, N.A., 60 F.3d 1245, 1247 (7th Cir.1995)). Referring to the factors that bear on attorneys’ fees that are discussed in the Manual for Complex Litigation (Third) § 24.121, at 190 (1995), I noted that this settlement created two large funds and benefitted many people; the objections were insubstantial; class counsel were able and efficient; the litigation was complex but fairly brief; and class counsel devoted much time to the case, but not a lot in view of the size of the settlement. Id. at 684.

As the Manual suggests, I also considered the awards in similar cases. I noted that there are few so-called “megafund” cases with settlements of over $100 million, but that in such cases, courts have been reluctant to award class counsel attorneys’ fees in the range of 22% or 29%, see id. at 684-85 (citing cases), first, because, other things being equal, such awards would be “an indefensible windfall,” id. (citing In the Matter of Superior Beverage, 133 F.R.D. 119, 124 (N.D.Ill.1990)), or “manifestly unjust,” id. (citing In re Unisys Corp. Retiree Med. Benefits ERISA Litig., 886 *865 F.Supp. 445, 462 (E.D.Pa.1995)). 1 Second, courts have thought that economies of scale kick in with additional recoveries on work expended, id. at 684 (citing In re Domestic Air Transp. Antitrust Litig., 148 F.R.D. 297, 351 (N.D.Ga.1993)), meaning that in a case of this size, lesser amounts of legal work are required for each additional dollar in the recovery. So I agreed with the Third Circuit Task Force on Court Awarded Attorney Fees that “absent unusual circumstances, the percentage will decrease as the size of the fund increases.” Id. (citing In re Chambers Dev. Sec. Litig., 912 F.Supp. 852, 861 (W.D.Pa.1995)). Accordingly, I observed, most awards in cases involving very large settlements had been in the 4-10% range. Id. (citing Unisys., 886 F.Supp. at 462).

I did not, however, state that the existence of this range implied a percentage cap as a matter of law on an attorneys’ fee award in a large settlement. Rather the rationale was an economic analysis. My reasoning was similar to that of the District of Wyoming, which said that when “a common fund is extraordinarily large, the application of a benchmark or standard percentage may result in a fee that is unreasonably large for the benefits conferred.” In re Copley Pharm., Inc., 1 F.Supp.2d 1407, 1413 (D.Wyo.1998) (citing Herbert P. Newberg, Attorney Fee Awards § 2.09 (1986)). As that court found, “empirical research ... reveals that courts are sensitive to this problem, reducing percentage awards as the size of the recovery increases.” Id. (citing William J. Lynk, The Courts and the Plaintiffs Bar: Awarding the Attorney’s Fee in Class-Action Litigation, 23 J. Legal Stud. 185, 201 (1994)). The issue is mainly one of economies of scale and diminishing marginal returns:

It is not one hundred fifty times more difficult to prepare, try, and settle a $150 million case than it is to try a $1 million case, but application of a percentage comparable to that in a smaller case [may] yield an award 150 times greater. Thus where fund recoveries range from $51-$75 million, fee awards usually fall in the 13-20% range. In megafund cases like this one, wherein a class recovers $75-$200 million (or more), courts most stringently weigh the economies of scale inherent in class actions in fixing a percentage yielding a recovery of reasonable fees. Accordingly, fees in the range of 6-10% and even lower are common in mega-common fund cases.

Id. (citing Newberg, at § 2.09; Lynk, 23 J. Legal Stud, at 201). Naturally, in a competitive market, economies of scale should be reflected in the market rate.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Taubenfeld v. Aon Corporation
Seventh Circuit, 2005
Vollmer, Thomas v. Selden, Lynde
350 F.3d 656 (Seventh Circuit, 2003)
Vollmer v. Selden
350 F.3d 656 (Seventh Circuit, 2003)
In the Matter Of: Synthroid Marketing Litigation
325 F.3d 974 (Seventh Circuit, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
201 F. Supp. 2d 861, 2002 U.S. Dist. LEXIS 8408, 2002 WL 1066355, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-synthroid-marketing-litigation-ilnd-2002.